Basic Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 7, 2022; 28(13): 1315-1328
Published online Apr 7, 2022. doi: 10.3748/wjg.v28.i13.1315
Jianpi Qingchang Bushen decoction improves inflammatory response and metabolic bone disorder in inflammatory bowel disease-induced bone loss
Ya-Li Zhang, Qian Chen, Lie Zheng, Zi-Wei Zhang, Yu-Jun Chen, Yan-Cheng Dai, Zhi-Peng Tang
Ya-Li Zhang, Qian Chen, Zi-Wei Zhang, Yu-Jun Chen, Zhi-Peng Tang, Institute of Digestive Diseases, LongHua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
Lie Zheng, Department of Gastroenterology, Traditional Chinese Medicine Hospital of Shaanxi Province, Xi’an 710003, Shaanxi Province, China
Yan-Cheng Dai, Department of Gastroenterology, Shanghai Traditional Chinese Medicine-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200082, China
Author contributions: Zhang YL and Chen Q contributed equally to this work, and both performed the majority of research; Dai YC, Zheng L, Zhang ZW, and Chen YJ performed the research and analyzed the data; Tang ZP designed and coordinated the research; Zhang YL and Chen Q wrote and revised the paper; all authors read and approved the final manuscript.
Supported by National Natural Science Foundation of China, No. 81704009 and No. 81873253; the Key Clinical Specialty Construction Project supported by Hongkou District Health Committee, No. HKZK2020A01; and the Sixth Round of Academic Experience Successors Training Project for Veteran Practitioner of Traditional Chinese Medicine (The Document of the State Administration of Traditional Chinese Medicine 2017), No. 29.
Institutional review board statement: The study was reviewed and approved by the Animal Ethics Committee of the Shanghai University of Traditional Chinese Medicine, No. PZSHUTCM191108004.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest related to this study.
Data sharing statement: The datasets generated during and/or analyzed during the current study will be available upon request from the principle investigator. The shared data will only be allowed to be used by the applicant for scientific studies. No commercial activities are allowed.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhi-Peng Tang, MD, PhD, Chief Doctor, Professor, Institute of Digestive Diseases, LongHua Hospital, Shanghai University of Traditional Chinese Medicine, No. 725 South Wanping Road, Shanghai 200032, China. zhipengtang@sohu.com
Received: September 20, 2021
Peer-review started: September 20, 2021
First decision: January 9, 2022
Revised: January 17, 2022
Accepted: February 27, 2022
Article in press: February 27, 2022
Published online: April 7, 2022
ARTICLE HIGHLIGHTS
Research background

In recent years, increasing attention has been paid to the study of osteopenia and osteoporosis caused by inflammatory bowel disease (IBD). Osteoporosis is one of the more common extra-intestinal manifestations in IBD patients. No effective preventive or treatment modality exists for osteoporosis in IBD patients. Therefore, we explored the possible pathogenesis of IBD-induced osteoporosis and evaluated the effectiveness of a promising drug in the present study.

Research motivation

Jianpi Qingchang Bushen decoction (JQBD) is a prescription developed by our team to treat IBD patients with osteoporosis. In this study, the potential pharmacodynamic mechanism of JQBD for treating IBD-induced osteoporosis was studied in vivo.

Research objectives

The effects of JQBD on the inflammatory response and bone metabolism were observed to provide a theoretical basis for the clinical prevention and treatment of osteoporosis in IBD patients.

Research methods

An IBD-induced osteoporosis model was constructed by treating interleukin-10-knockout mice with piroxicam. JQBD was given as an intervention, and its effect on the inflammatory response and bone metabolism was observed.

Research results

Our data show that JQBD was protective against IBD-induced bone loss by inhibiting inflammation. The receptor activator of nuclear factor kappa B (NF-κB) ligand (RANKL), osteoprotegerin (OPG), receptor activator of NF-κB (RANK), and NF-κB protein levels increased significantly in colon tissue from the model group. Their expression levels were downregulated after JQBD intervention.

Research conclusions

We evaluated the curative effects of JQBD on the bone-loss IBD model mice and confirmed that the RANK/RANKL/OPG signaling pathway is involved in the process.

Research perspectives

This study primarily focused on the mechanism by which JQBD regulates the RANK/RANKL/OPG signaling pathway and improves IBD-induced osteoporosis.